Ayurcann Holdings Past Earnings Performance
Past criteria checks 0/6
Ayurcann Holdings's earnings have been declining at an average annual rate of -43.2%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 41.8% per year.
Key information
-43.2%
Earnings growth rate
-16.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 41.8% |
| Return on equity | -741.8% |
| Net Margin | -15.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Even With A 88% Surge, Cautious Investors Are Not Rewarding Ayurcann Holdings Corp.'s (CSE:AYUR) Performance Completely
Jun 28
Not Many Are Piling Into Ayurcann Holdings Corp. (CSE:AYUR) Stock Yet As It Plummets 33%
May 11Market Cool On Ayurcann Holdings Corp.'s (CSE:AYUR) Revenues Pushing Shares 29% Lower
Mar 22Revenue & Expenses Breakdown
How Ayurcann Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -4 | 11 | 0 |
| 31 Mar 24 | 23 | -4 | 11 | 0 |
| 31 Dec 23 | 20 | -5 | 11 | 0 |
| 30 Sep 23 | 17 | -5 | 9 | 0 |
| 30 Jun 23 | 12 | -5 | 9 | 0 |
| 31 Mar 23 | 10 | -5 | 7 | 0 |
| 31 Dec 22 | 10 | -4 | 6 | 0 |
| 30 Sep 22 | 10 | -4 | 6 | 0 |
| 30 Jun 22 | 9 | -3 | 6 | 0 |
| 31 Mar 22 | 10 | 0 | 4 | 0 |
| 31 Dec 21 | 10 | 0 | 4 | 0 |
| 30 Sep 21 | 9 | 0 | 3 | 0 |
| 30 Jun 21 | 8 | 0 | 2 | 0 |
| 31 Mar 21 | 6 | -1 | 2 | 0 |
| 30 Jun 20 | 1 | -1 | 0 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
Quality Earnings: AYUR is currently unprofitable.
Growing Profit Margin: AYUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AYUR is unprofitable, and losses have increased over the past 5 years at a rate of 43.2% per year.
Accelerating Growth: Unable to compare AYUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYUR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: AYUR has a negative Return on Equity (-741.8%), as it is currently unprofitable.